College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Manitoba, Canada.
Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Manitoba, Canada.
Inflamm Bowel Dis. 2021 Jan 1;27(1):58-64. doi: 10.1093/ibd/izaa014.
Substance use disorders (SUDs) impose a substantial individual and societal burden; however, the prevalence and associated factors in persons with inflammatory bowel disease (IBD) are largely unknown. We evaluated the prevalence and risk factors of SUD in an IBD cohort.
Inflammatory bowel disease participants (n = 247) were recruited via hospital- and community-based gastroenterology clinics, a population-based IBD research registry, and primary care providers as part of a larger cohort study of psychiatric comorbidity in immune-mediated inflammatory diseases. The Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders IV was administered to participants to identify lifetime SUD, anxiety disorder, and major depressive disorder. Additional questionnaires regarding participants' sociodemographic and clinical characteristics were also completed. We examined demographic and clinical factors associated with lifetime SUD using unadjusted and adjusted logistic regression modeling.
Forty-one (16.6%) IBD participants met the criteria for a lifetime diagnosis of an SUD. Factors associated with elevated odds of SUD were ever smoking (adjusted odds ratio [aOR], 2.96; 95% confidence interval [CI], 1.17-7.50), male sex (aOR, 2.44; 95% CI, 1.11-5.36), lifetime anxiety disorder (aOR, 2.41; 95% CI, 1.08-5.37), and higher pain impact (aOR, 1.08; 95% CI, 1.01-1.16).
One in six persons with IBD experienced an SUD, suggesting that clinicians should maintain high index of suspicion regarding possible SUD, and inquiries about substance use should be a part of care for IBD patients, particularly for men, smokers, and patients with anxiety disorders and pain.
物质使用障碍(SUD)给个人和社会带来了巨大的负担;然而,炎症性肠病(IBD)患者中 SUD 的患病率和相关因素在很大程度上尚不清楚。我们评估了 IBD 患者队列中 SUD 的患病率和危险因素。
炎症性肠病参与者(n = 247)通过医院和社区胃肠病学诊所、基于人群的 IBD 研究登记处以及初级保健提供者招募,作为免疫介导的炎症性疾病中精神共病的更大队列研究的一部分。使用诊断和统计手册第四版的结构化临床访谈(SCID-IV)对参与者进行评估,以确定终生 SUD、焦虑症和重度抑郁症。还完成了关于参与者社会人口统计学和临床特征的其他问卷。我们使用未调整和调整后的逻辑回归模型检查了与终生 SUD 相关的人口统计学和临床因素。
41 名(16.6%)IBD 参与者符合终生 SUD 诊断标准。与 SUD 风险升高相关的因素包括吸烟(调整后的优势比 [aOR],2.96;95%置信区间 [CI],1.17-7.50)、男性(aOR,2.44;95% CI,1.11-5.36)、终生焦虑症(aOR,2.41;95% CI,1.08-5.37)和更高的疼痛影响(aOR,1.08;95% CI,1.01-1.16)。
六分之一的 IBD 患者经历过 SUD,这表明临床医生应保持对可能的 SUD 的高度怀疑,并且对物质使用的询问应该成为 IBD 患者护理的一部分,特别是对男性、吸烟者以及患有焦虑症和疼痛的患者。